BioNTech Stock Rises After Earnings. Pfizer's Vaccine Partners Is Battling a Covid Downturn.

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 51 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 97%

مصر أخبار أخبار

مصر أحدث الأخبار,مصر عناوين

Shares have dropped 36% this year as demand for its coronavirus inoculations has fallen.

BioNTech, the German pharmaceutical company that partnered with Pfizer to create a Covid-19 vaccine, posted a surprise earnings beat.

For the third quarter, earnings per share came in at 0.67 euros , compared with analysts’ expectations for a loss in the period. Revenue also topped estimates, at €895 million , though both figures were lower than a year ago. The company also said that it wouldn’t have to take as big a hit on its Covid-19 vaccines as it thought just a few weeks ago. It said it would reduce third-quarter revenues by €508 million after Pfizer reported writedowns on their joint product. It initially said it could be about €900 million.

BioNTech U.S.-listed shares jumped more than 3% in premarket trading. BioNTech stock has declined 36% this year. Pfizer , which reported disappointing earnings last week, was up 0.2% in early trading Monday. Covid-19 vaccine makers have been shunned after their meteoric rise during the pandemic. BioNTech and peers such as Pfizer and Moderna are having trouble convincing investors they are more than one-trick ponies.Write to Brian Swint at brian.swint@barrons.com

لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 3. in EG
 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.

مصر أحدث الأخبار, مصر عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Pfizer Covid Vaccine Partner BioNTech's Stock Is Rising After Earnings BeatShares have dropped 36% this year as demand for its coronavirus inoculations has fallen.
مصدر: MarketWatch - 🏆 3. / 97 اقرأ أكثر »